EuroBiotech: More Articles of Note


> Alizé Pharma 3 raised a €67 million ($75 million) series A round. The French biotech will use the money to move two candidates into the clinic next year. Statement (PDF)

> Johnson & Johnson returned the rights to anti-CD40 antibody ADC-1013 to Alligator Bioscience. J&J took the drug through a phase 1 trial before deciding to prioritize other assets. Release 

> A phase 3 trial of Atlantic Healthcare’s Camligo in orphan-designated pouchitis missed its co-primary endpoints. Despite the failure, Atlantic plans to meet with regulators to discuss a pathway to approval. Statement 

> Regulators on both sides of the Atlantic granted orphan drug designation to Genfit’s elafibranor in primary biliary cholangitis. Genfit plans to start a phase 3 trial in the indication later this year. Release 

> Iontas entered into an antibody optimization deal with Teva. The work will focus on antibodies against a defined target of interest to Teva. Statement